Insider Selling: Moderna (NASDAQ:MRNA) President Sells 39,160 Shares of Company Stock

Moderna logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Moderna President Stephen Hoge sold 39,160 shares for about $8.6 million at an average price of $219.66 under a pre-arranged Rule 10b5-1 plan. He retained 1,673,858 shares after the sale.
  • Moderna shares fell $10.01 to $196.79 in Wednesday trading. The company reported quarterly revenue of $1.31 billion, up 29.2% year over year, and EPS of $0.38, beating analyst estimates.
  • Analyst sentiment was mixed, with a consensus “Hold” rating and an average price target of $120.25. The article also notes positive Phase 3 data for Moderna’s personalized melanoma treatment with Keytruda.
  • Interested in Moderna? Here are five stocks we like better.

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) President Stephen Hoge sold 39,160 shares of the company's stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $219.66, for a total transaction of $8,601,885.60. Following the sale, the president owned 1,673,858 shares in the company, valued at $367,679,648.28. The trade was a 2.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

  • On Tuesday, November 17th, Stephen Hoge sold 39,215 shares of Moderna stock. The shares were sold at an average price of $211.61, for a total transaction of $8,298,286.15.
  • On Thursday, October 15th, Stephen Hoge sold 39,145 shares of Moderna stock. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40.
  • On Wednesday, October 14th, Stephen Hoge sold 39,224 shares of Moderna stock. The shares were sold at an average price of $213.48, for a total transaction of $8,373,539.52.
  • On Monday, September 14th, Stephen Hoge sold 40,294 shares of Moderna stock. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22.
  • On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The shares were sold at an average price of $146.07, for a total value of $5,883,845.67.

Moderna Stock Performance

Shares of NASDAQ:MRNA traded down $10.01 during midday trading on Wednesday, reaching $196.79. 6,901,633 shares of the company traded hands, compared to its average volume of 12,504,324. The firm's fifty day moving average price is $204.39 and its two-hundred day moving average price is $98.06. The firm has a market capitalization of $79.63 billion, a price-to-earnings ratio of -27.72 and a beta of 1.16. The company has a quick ratio of 3.47, a current ratio of 3.62 and a debt-to-equity ratio of 0.52. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $280.80.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. During the same quarter last year, the company earned ($0.51) EPS. The firm's revenue was up 29.2% compared to the same quarter last year. On average, equities analysts expect that Moderna, Inc. will post -5.14 earnings per share for the current year.

Analysts Set New Price Targets

MRNA has been the topic of several recent analyst reports. William Blair cut shares of Moderna from an "outperform" rating to a "market perform" rating in a research note on Tuesday, October 27th. Jefferies Financial Group restated a "hold" rating and set a $150.00 price target (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Rothschild & Co Redburn cut shares of Moderna from a "neutral" rating to a "sell" rating and upped their price target for the stock from $40.00 to $81.00 in a report on Thursday, September 3rd. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $130.00 price objective on shares of Moderna in a research report on Wednesday, August 19th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Moderna in a research report on Wednesday, September 9th. Six research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $120.25.

Read Our Latest Report on MRNA

Trending Headlines about Moderna

These are some of the MRNA headlines that stood out recently:

Institutional Trading of Moderna

A number of hedge funds have recently made changes to their positions in MRNA. Ethic Inc. grew its position in Moderna by 23.6% in the 3rd quarter. Ethic Inc. now owns 19,394 shares of the company's stock worth $3,735,000 after purchasing an additional 3,700 shares during the period. Merck & Co. Inc. purchased a new stake in Moderna during the 2nd quarter valued at $161,642,545. Bank of New York Mellon Corp purchased a new stake in Moderna during the 2nd quarter valued at $119,168,000. Contravisory Investment Management Inc. lifted its holdings in shares of Moderna by 1,387.6% during the 2nd quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company's stock valued at $1,696,000 after buying an additional 22,590 shares during the period. Finally, TD Waterhouse Canada Inc. lifted its holdings in shares of Moderna by 2,042.6% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company's stock valued at $13,722,000 after buying an additional 69,203 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Read More

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Moderna Right Now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines